A Biomarker‐Based Dose–Schedule Optimization Design for Immunotherapy Trials
Statistics in Medicine · 2026
DOI: 10.1002/sim.70357 ↗At a glance
Journal article in Statistics in Medicine, 2026. Written by Yingjie Qiu and 2 co-authors. Institution: Peter O'Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dallas, Texas, USA. Major MEDLINE topics: Immunotherapy, Biomarkers, Clinical Trials as Topic. Cited 2 times so far (Crossref); 46 references. The full text is freely available (open access, CC BY 4.0). Funded by: NCI NIH HHS, Indiana Clinical and Translational Sciences Institute, National Cancer Institute.
Abstract (original language)
In immunotherapy, both the dose and the schedule of drug administration can significantly influence therapeutic effects by modulating immune system activation. Incorporating immune response measures into clinical trial designs offers an opportunity to enhance decision‐making by leveraging their close association with therapeutic efficacy and toxicity. Motivated by settings where biomarker data indicate improved efficacy in biomarker‐positive patients, we propose a dose–schedule optimization strategy tailored to each biomarker‐defined subgroup, based on elicited utility functions that capture risk‐benefit tradeoffs. We introduce a joint modeling framework that simultaneously evaluates immune response, toxicity, and efficacy, enabling information sharing across outcome types and patient subgroups. Our approach utilizes parsimonious yet flexible models designed specifically to address challenges due to small sample sizes commonly encountered in early‐phase trials. Simulation studies demonstrate that the proposed design achieves desirable operating characteristics and effectively informs dose–schedule optimization.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Peter O'Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
- Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
- Department of Biostatistics and Health Data Science, Indiana University, Indianapolis, Indiana, USA.
- Department of Experimental Statistics, Louisiana State University, Baton Rouge, Louisiana, USA.
ORCID profiles: Yingjie Qiu, Beibei Guo
Funding
- NCI NIH HHS
- Indiana Clinical and Translational Sciences Institute
- National Cancer Institute
Cite
APA
Qiu, Y., Han, Y., & Guo, B. (2026). A Biomarker‐Based Dose–Schedule Optimization Design for Immunotherapy Trials. Statistics in Medicine. https://doi.org/10.1002/sim.70357
Vancouver
Qiu Y, Han Y, Guo B. A Biomarker‐Based Dose–Schedule Optimization Design for Immunotherapy Trials. Statistics in Medicine. 2026. doi:10.1002/sim.70357
BibTeX
@article{Qiu2026,
author = {Qiu, Yingjie and Han, Yan and Guo, Beibei},
title = {A Biomarker‐Based Dose–Schedule Optimization Design for Immunotherapy Trials},
journal = {Statistics in Medicine},
year = {2026},
doi = {10.1002/sim.70357}
}
EUVIMED